HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The use of encainide in atrial fibrillation.

Abstract
Based on its electrophysiologic characteristics, encainide, a new type 1 antiarrhythmic agent, was selected for a therapeutic trial in a case of refractory paroxysmal atrial fibrillation. This approach represents an attempt to manage the pathophysiologic disturbance of atrial fibrillation by selection of a drug that would be expected to have specific effects on the conduction system.
AuthorsS C Vlay, P R Reid
JournalClinical cardiology (Clin Cardiol) Vol. 7 Issue 9 Pg. 498-502 (Sep 1984) ISSN: 0160-9289 [Print] United States
PMID6442224 (Publication Type: Case Reports, Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Anilides
  • Anti-Arrhythmia Agents
  • Verapamil
  • Encainide
Topics
  • Anilides (therapeutic use)
  • Anti-Arrhythmia Agents (therapeutic use)
  • Atrial Fibrillation (drug therapy, physiopathology)
  • Encainide
  • Humans
  • Male
  • Verapamil (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: